Merck’s Treatment For Rare NSCLC Gains FDA Breakthrough Therapy Designation

By John Heerdink LinkedIn

Reportedly, Merck KgaA’s tepotinib, a treatment for the MET exon14 skipping mutation in the genetic makeup of a lung tumor, has been awarded the U.S. Food and Drug Administration’s breakthrough therapy designation. Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. This particular indication is estimated to represent between 3%-5% of non-small cell lung (NSCLC) cancer cases in aggregate.

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some the of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website:www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Sign Up to receive FREE email updates here!

sep14

Merck KGaA lung cancer drug is 3rd on U.S. watchdog’s priority lane

Merck KGaA’s prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration’s breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track..

finance.yahoo.com

Read Full Article
Post View Count : 287


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us